Evolving Paradigms in Lymphoma: References

Evolving Paradigms, Lymphoma, Volume 1, Issue 1

This feature covers the "References" section of the current Evolving Paradigms in Lymphoma issue.


  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015.CA Cancer J Clin. 2015;65(1):5-29.
  2. National Cancer Institute. SEER Stat Fact Sheets: Hodgkin Lymphoma. Bethesda, Maryland; 2015. http://seer.cancer.gov/statfacts/html/hodg.html. Accessed Au- gust 14, 2015.
  3. Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma.Ann Oncol. 2015;26(10):2026-2033.
  4. Townsend W, Linch D. Hodgkin’s lymphoma in adults.Lancet. 2012;380(9844):836- 847.
  5. National Cancer Institute. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. Bethes- da, Maryland; 2015. http://seer.cancer.gov/statfacts/html/nhl.html. Accessed July 15, 2015.
  6. Müller AMS, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodg- kin’s lymphoma (NHL): trends, geographic distribution, and etiology.Ann Hematol. 2005;84(1):1-12.
  7. Ambinder RF. Infectious etiology of lymphoma. In: Non-Hodgkin Lymphomas. 2nd ed. Wolters Kluwer and Lippincott Williams and Wilkins; 2010, pp 83-101.
  8. Swerdlow S, Campo E, Harris N, et al.WHO Classification of Tumours of Haemato- poietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
  9. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma.Lancet. 2012;380(9844):848-857.
  10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma; 2015. www.nccn.org/professionals/physician_gls/ pdf/nhl.pdf. Accessed August 15, 2015.
  11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas; 2015. www.nccn.org/professionals/physi- cian_gls/pdf/nhl.pdf. Accessed August 15, 2015.
  12. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by
  13. WHO-classification.Blood. 2003;101(10):3875-3876.
13. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.Blood. 2008;112(10):3989-3994.
  14. Wu L-M, Chen F-Y, Jiang X-X, Gu H-Y, Yin Y, Xu J-R. 18F-FDG PET, combined FDG- PET/CT and MRI for evaluation of bone marrow infiltration in staging of lympho- ma: a systematic review and meta-analysis.Eur J Radiol. 2012;81(2):303-311.
  15. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lym- phoma. A bicenter trial.Cancer. 2001;91(5):889-899.
  16. Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Inter- gruppo Italiano Linfomi.Ann Hematol. 2007;86(12):897-903.
  17. Cerci JJ, Trindade E, Buccheri V, et al. Consistency of FDG-PET accuracy and cost- effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdic- tions.Clin Lymphoma Myeloma Leuk. 2011;11(4):314-320.
  18. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D- glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study.J Clin Oncol. 2007;25(24):3746-3752.
  19. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma.Leuk Lymphoma. 2009;50(8):1257-1260.
  20. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Com- mittee on Hodgkin’s Disease Staging Classification.Cancer Res. 1971;31(11):1860- 1861.
  21. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting.J Clin Oncol. 1989;7(11):1630-1636.
  22. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma.N Engl J Med. 2010;363(7):640-652.
  23. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. Inter- national Prognostic Factors Project on Advanced Hodgkin’s Disease.N Engl J Med. 1998;339(21):1506-1514.
  24. Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodg- kin lymphoma: A 50-year perspective.J Clin Oncol. 2014;32(3):163-168.
  25. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329(14):987-994.
  26. Solal-Céligny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prog- nostic Index.Blood. 2004;104(5):1258-1265.
  27. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med. 2002;346(25):1937-1947.
  28. Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.Adv Anat Pathol. 2015;22(1):29-49.
  29. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18—fluorodeoxyglucose positron emission tomography.J Clin Oncol. 2005;23(21):4652-4661.
  30. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.J Clin Oncol. 2014; 32(27):3048- 3058:
  31. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavor- able Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.J Clin Oncol. 2012;30(9):907-913.
  32. Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a “negative” PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. Presented at: 2012 ASH Annual Meeting; Atlanta, GA; December 8-11, 2012. Abstract 547.
  33. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lym- phoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.J Clin Oncol. 2009;27(5):805-811.
  34. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis.Lancet Oncol. 2013;14(10):943-952.
  35. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned.N Engl J Med. 2011;365(3):203-212.
  36. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma.Blood. 2011;117(16):4208-4217.
  37. Armitage JO. Early-stage Hodgkin’s lymphoma.N Engl J Med. 2010;363(7):653-662.
  38. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associ- 
ated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed- Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.Blood. 1985;66(4):848-858.
  39. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30—mono- methyl auristatin E conjugate with potent and selective antitumor activity.Blood. 2003;102(4):1458-1465.
  40. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.N Engl J Med. 2010;363(19):1812-1821.
  41. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentux- imab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma.J Clin Oncol. 2012;30(18):2183-2189.
  42. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolida- tion therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double- blind, placebo-controlled, phase 3 trial.Lancet. 2015;385(9980):1853-1862.
  43. US Food and Drug Administration. Brentuximab Vedotin Approval. August 2015. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm458815. htm. Accessed August 19, 2015.
  44. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—pre- clinical background: CTLA-4 and PD-1 blockade.Semin Oncol. 2010;37(5):430-439.
  45. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in re- lapsed or refractory Hodgkin’s lymphoma.N Engl J Med. 2015;372(4):311-319.
  46. Coiffier B, Lepage E, Brière J, et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002;346(4):235-242.
  47. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.J Clin Oncol. 2006;24(19):3121-3127.
  48. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High-dose che- motherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.Cochrane Database Syst Rev. 2008;(1):CD004024.
  49. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).Lancet Oncol. 2008;9(2):105-116.
  50. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype
in newly diagnosed diffuse large B-cell lymphoma: a phase II study.J Clin Oncol. 2015;33(3):251-257.
  51. Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.Lancet Oncol. 2014;15(9):1019-1026.
  52. Hagberg H, Gisselbrecht C, CORAL study group. Randomised phase III study of R- ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to mainte- nance treatment with rituximab or not: an update of the CORAL study.Ann Oncol. 2006;17(suppl 4):iv31-iv32.
  53. Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.J Clin Oncol. 2012;30(36):4462-4469.
  54. van Kampen RJW, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.J Clin Oncol. 2011;29(10):1342-1348.
  55. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy.Int J Radiat Oncol Biol Phys. 2006;64(3):928-934.
  56. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lym- phoma transformation in the immunochemotherapy era: a report from the Univer- sity of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.J Clin Oncol. 2013;31(26):3272-3278.
  57. Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor bur- den follicular lymphoma in the rituximab era: results of an F2-study database.J Clin Oncol. 2012;30(31):3848-3853.
  58. Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.Lancet Oncol. 2014;15(4):424-435.
  59. Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.J Clin Oncol. 2014;32(28):3096-3102.
  60. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine- rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.Blood. 2014;123(19):2944-2952.
  61. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in pa- tients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.Lancet. 2011;377(9759):42-51.
  62. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol. 2008;26(32):5156-5164.
  63. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial.J Clin Oncol. 2003;21(21):3918-3927.
  64. Evens AM, Vanderplas A, LaCasce AS, et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.Cancer. 2013;119(20):3662-3671.
  65. Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointesti- nal involvement and its clinical significance in mantle cell lymphoma.Cancer. 2003;97(3):586-591.
  66. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma.J Clin Oncol. 2009;27(8):1209-1213.
  67. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non- inferiority trial.Lancet. 2013;381(9873):1203-1210.
  68. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmu- notherapy with rituximab-hyperCVAD alternating with rituximab-high dose metho- trexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.Br J Haematol. 2010;150(2):200-208.
  69. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radio- chemotherapy followed by autologous stem cell transplantation in first remis- sion significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.Blood. 2005;105(7):2677-2684.
  70. Ansell SM. Non-Hodgkin lymphoma: diagnosis and treatment.Mayo Clin Proc. 2015;90(8):1152-1163.
  71. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clini- cally and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.Blood. 2008;111(12):5496-5504.
  72. Zhang X-M, Li Y-X, Wang W-H, et al. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.Eur J Haematol. 2013;90(3):195-201.
  73. Hapgood G, Savage KJ. The biology and management of systemic anaplastic large 
cell lymphoma.Blood. 2015;126(1):17-25.
  74. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors 
and treatment in peripheral T-cell lymphomas: a study from the Swedish Lym- 
phoma Registry.Blood. 2014;124(10):1570-1577.
  75. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell 
and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.Blood. 2010;116(18):3418-3425.
  76. Eyre TA, Khan D, Hall GW, Collins GP. Anaplastic lymphoma kinase-positive ana- plastic large cell lymphoma: current and future perspectives in adult and paediat- ric disease.Eur J Haematol. 2014;93(6):455-468.
  77. Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for sys- temic mature T-cell non-Hodgkin lymphoma.J Clin Oncol. 2013;31(25):3100-3109.
  78. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratifi- cation, and treatment.Am J Hematol. 2015;90(5):446-460.
  79. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia—what do we need to know?Nat Rev Clin Oncol. 2011;8(1):38-47.
  80. CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lym- phocytic leukemia: a meta-analysis of the randomized trials.J Natl Cancer Inst. 1999;91(10):861-868.
  81. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus ritux- imab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.Lancet Oncol. 2014;15(10):1090-1099.
  82. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med. 2013;369(1):32-42.
  83. Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transi- tion to a new treatment era: stem cell transplantation or novel agents?Blood. 2014;124(26):3841-3849.
  84. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Br J Haematol. 2009;146(2):171-179.
  85. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.J Clin Oncol. 2012;30(18):2190-2196.
  86. Pro B, Advani R, Brice P, et al. Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic ana- plastic large cell lymphoma. December 2013. https://ash.confex.com/ash/2013/ webprogram/Paper57591.html. Accessed August 19, 2015.
  87. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.N Engl J Med. 2014;370(12):1101-1110.
  88. Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood. 2011;117(2):591-594.
  89. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Blood. 2014;123(22):3390-3397.
  90. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphati- dylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Blood. 2014;123(22):3406-3413.
  91. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med. 2014;370(11):1008-1018.
  92. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).Blood. 2014;123(22):3398-3405.
  93. FurmanRR,SharmanJP,CoutreSE,etal.Idelalisibandrituximabinrelapsed chronic lymphocytic leukemia.N Engl J Med. 2014;370(11):997-1007.
  94. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma.Clin Cancer Res. 2007;13(18):5291-5294.
  95. Cavalli F, Rooney B, Pei L, Van De Velde H, Robak T. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R- CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).J Clin Oncol. 2014: Abstract 8500.
  96. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon- DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.Nat Struct Mol Biol. 2014;21(9):803-809.
  97. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.Br J Haematol. 2009;145(3):344-349.
  98. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma.Ann Oncol. 2011;22(7):1622-1627.
  99. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.J Clin Oncol. 2013;31(29):3688-3695.
  100. Katz B-Z, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.Leuk Lymphoma. 2014;55(5):999-1006.
  101. Hijazi Y, Klinger M, Schub A, et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL).J Clin Oncol. 2013. http://meetinglibrary.asco.org/content/110626-132. Accessed August 13, 2015.
  102. ClinicalTrials.gov. Clinical study with blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). https://clinicaltrials.gov/ct2/show/NCT01741792. Accessed August 13, 2015.
  103. ClinicalTrials.gov. A study of GDC-0199 (ABT-199) plus MabThera/Rituxan (rituximab) compared with bendamustine plus MabThera/Rituxan (Rituximab) in patients with relapsed or refractory chronic lymphocytic leukemia. https://clini- caltrials.gov/ct2/show/NCT02005471. Accessed August 13, 2015.
  104. ClinicalTrials.gov. A study evaluating the safety and pharmacokinetics of ABT-199 in combination with bendamustine/rituximab (BR) in subjects with relapsed
or refractory non-Hodgkin’s lymphoma. https://clinicaltrials.gov/ct2/show/ NCT01594229. Accessed August 20, 2015.
  105. ClinicalTrials.gov. A study evaluating the safety and efficacy of GDC-0199 (ABT- 199) plus bendamustine + rituximab (BR) in comparison with BR or GDC-0199 plus rituximab in patients with relapsed and refractory follicular non-Hodgkin’s lymphoma. https://clinicaltrials.gov/ct2/show/NCT02187861. Accessed August 20, 2015.
  106. ClinicalTrials.gov. Optimal dose finding study ABT-199 and ibrutinib in MCL. https://clinicaltrials.gov/ct2/show/NCT02419560. Accessed August 20, 2015.
  107. ClinicalTrials.gov. Carfilzomib plus belinostat in relapsed/refractory NHL. https:// clinicaltrials.gov/ct2/show/NCT02142530. Accessed August 20, 2015.
  108. ClinicalTrials.gov. EPOCH-R chemotherapy plus bortezomib to treat mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT00114738. Accessed August 16, 2015.
  109. ClinicalTrials.gov. A randomised evaluation of molecular guided therapy for dif- fuse large B-cell lymphoma with bortezomib. https://clinicaltrials.gov/ct2/show/ NCT01324596. Accessed August 20, 2015.
  110. ClinicalTrials.gov. Brentuximab vedotin and bendamustine for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). https://clinicaltri- als.gov/ct2/show/NCT01657331. Accessed August 20, 2015.
  111. ClinicalTrials.gov. Brentuximab vedotin and lenalidomide for relapsed or refractory diffuse large B-cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT02086604. Accessed August 20, 2015.
  112. ClinicalTrials.gov. A phase II study of carfilzomib in the treatment of relapsed/re- fractory mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT02042950. Accessed August 20, 2015.
  113. ClinicalTrials.gov. carfilzomib, rituximab, ifosfamide, carboplatin, and etoposide in treating patients with relapsed or refractory diffuse large B-cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT01959698. Accessed August 20, 2015.
  114. ClinicalTrials.gov. A study of treatment ALK(+) systemic anaplastic large cell lymphoma with crizotinib. https://clinicaltrials.gov/ct2/show/NCT02487316. Accessed August 20, 2015.
  115. ClinicalTrials.gov. Study of duvelisib in combination with rituximab vs rituximab in subjects with previously treated follicular lymphoma (DYNAMO + R). https:// clinicaltrials.gov/ct2/show/NCT02204982. Accessed August 13, 2015.
  116. ClinicalTrials.gov. A phase 3 study of duvelisib versus ofatumumab in patients with relapsed or refractory CLL/SLL (DUO). https://clinicaltrials.gov/ct2/show/NCT02004522. Accessed August 13, 2015.
  117. ClinicalTrials.gov. A phase 2 of entospletinib in subjects with relapsed or refrac- 
tory hematologic malignancies. https://clinicaltrials.gov/ct2/show/NCT01799889. 
Accessed August 20, 2015.
  118. ClinicalTrials.gov. Everolimus in combination with DHAP in patients with re- 
lapsed or refractory Hodgkin lymphoma. https://clinicaltrials.gov/ct2/show/ 
NCT01453504. Accessed August 20, 2015.
  119. ClinicalTrials.gov. Ibrutinib and combination chemotherapy in treating patients 
with relapsed or refractory diffuse large B-cell lymphoma. https://clinicaltrials. 
gov/ct2/show/NCT02219737. Accessed August 20, 2015.
  120. ClinicalTrials.gov. Combination of ibrutinib and bortezomib to treat patients with 
mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT02356458. Ac- 
cessed August 20, 2015.
  121. ClinicalTrials.gov. Idelalisib in combination with rituximab for previously untreat- 
ed follicular lymphoma and small lymphocytic lymphoma. https://clinicaltrials. 
gov/ct2/show/NCT02258529. Accessed August 20, 2015.
  122. ClinicalTrials.gov. Treatment of patients with diffuse large B cell lymphoma who 
are not suitable for anthracycline containing chemotherapy (INCA). https://clini- 
caltrials.gov/ct2/show/NCT01679119. Accessed August 13, 2015.
  123. ClinicalTrials.gov. Clinical trial to determinate dose, security and efficacy of 
lenalidomide and rituximab (LR)-ESHAP in patients with diffuse large B-cell lym- phoma. https://clinicaltrials.gov/ct2/show/NCT02340936. Accessed August 20, 2015.
  124. ClinicalTrials.gov. Lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance for relapsed/refractory follicular, marginal zone or mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT01996865. Accessed Au- gust 20, 2015.
  125. ClinicalTrials.gov. Study of nivolumab in subjects with Hodgkin’s lymphoma (Reg- istrational) (CheckMate 205). https://clinicaltrials.gov/ct2/show/NCT02181738. Accessed August 13, 2015.
  126. ClinicalTrials.gov. Study of nivolumab in patients with relapsed or refractory dif- fuse large B-cell lymphoma (DLBCL) that have either failed or are not eligible for autologous stem cell transplant (CheckMate 139). https://clinicaltrials.gov/ct2/ show/NCT02038933. Accessed August 13, 2015.
  127. ClinicalTrials.gov. Study of nivolumab in subjects with relapsed or refractory follicular lymphoma (FL) (CheckMate 140). https://clinicaltrials.gov/ct2/show/ NCT02038946. Accessed August 13, 2015.
  128. ClinicalTrials.gov. Obinutuzumab and ICE chemotherapy in refractory/recurrent CD20+ mature NHL. https://clinicaltrials.gov/ct2/show/NCT02393157. Accessed August 20, 2015.
  129. ClinicalTrials.gov. Study of obinutuzumab + chlorambucil, ACP-196 + obinutuzum- ab, and ACP-196 in subjects with previously untreated CLL. https://clinicaltrials. gov/ct2/show/NCT02475681. Accessed August 20, 2015.
  130. ClinicalTrials.gov. Ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B-cell non-Hodgkin’s lymphoma (NHL) unresponsive to rituximab or a rituximab-containing regimen. https://clini- caltrials.gov/ct2/show/NCT01077518. Accessed August 20, 2015.
  131. ClinicalTrials.gov. Ofatumumab with or without bendamustine for patients with mantle cell lymphoma ineligible for autologous stem cell transplant. https://clini- caltrials.gov/ct2/show/NCT01437709. Accessed August 13, 2015.
  132. ClinicalTrials.gov. Rapid infusion of ofatumumab in patients with previously treated chronic lymphocytic leukemia. https://clinicaltrials.gov/ct2/show/ NCT01848145. Accessed August 20, 2015.
  133. ClinicalTrials.gov. Panobinostat plus ifosfamide, carboplatin, and etoposide (ICE) compared with ICE for relapsed Hodgkin lymphoma. https://clinicaltrials.gov/ct2/ show/NCT01169636. Accessed August 20, 2015.
  134. ClinicalTrials.gov. Pembrolizumab after ASCT for Hodgkin lymphoma and DLBCL. https://clinicaltrials.gov/ct2/show/NCT02362997. Accessed August 13, 2015.
  135. ClinicalTrials.gov. A study of polatuzumab vedotin (DCDS4501A) in combination with rituximab or obinutuzumab plus bendamustine in patients with relapsed or refractory follicular or diffuse large B-cell lymphoma. https://clinicaltrials.gov/ ct2/show/NCT02257567. Accessed August 20, 2015.
  136. ClinicalTrials.gov. STORM: Temsirolimus, rituximab and DHAP for relapsed and refractory diffuse large B-cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT01653067. Accessed August 20, 2015.
  137. ClinicalTrials.gov. Temsirolimus for relapsed/refractory Hodgkin’s lymphoma. https://clinicaltrials.gov/ct2/show/NCT00838955. Accessed August 20, 2015.
  138. ClinicalTrials.gov. Temsirolimus, bendamustine and rituximab for relapsed follicular lymphoma or mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT01078142. Accessed August 20, 2015.
  139. Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.Blood. 2012;119(18):4123-4128.
  140. Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Lancet Oncol. 2014;15(12):1311-1318.
  141. Borchmann P, Haverkamp H, Lohri A. Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: Second planned interim analysis of the HD18 study. In: Vol ; 2014. https://ash.confex.com/ash/2014/webprogram/Paper74038.html.
  142. ClinicalTrials.gov. Study of rituximab and brentuximab vedotin for relapsed clas- sical Hodgkin lymphoma. https://clinicaltrials.gov/ct2/show/NCT01900496. Accessed August 13, 2015.
  143. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.Blood. 2011;118(19):5126-5129.
  144. Barth MJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma [published online ahead of print May 11, 2015].Clin Cancer Res. PMID: 25964296.
  145. Furtado M, Dyer MJS, Johnson R, Berrow M, Rule S. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma—a phase II trial.Br J Haematol. 2014;165(4):575-578.
  146. ClinicalTrials.gov. Ofatumumab in combination with cyclophosphamide, doxo- rubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate in treating patients with newly diagnosed mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/ NCT01527149. Accessed August 13, 2015.
  147. ClinicalTrials.gov. Ofatumumab versus rituximab salvage chemoimmunotherapy followed by autologous stem cell transplant in relapsed or refractory diffuse large B cell lymphoma (ORCHARRD). https://clinicaltrials.gov/ct2/show/NCT01014208. Accessed August 13, 2015.
  148. Micallef INM, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.Blood. 2011;118(15):4053-4061.
  149. Grant BW, Jung S-H, Johnson JL, et al. A phase II trial of extended induction epratu- zumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.Cancer. 2013;119(21).
  150. ClinicalTrials.gov. Study of veltuzumab and 90Y-epratuzumab in relapsed/refrac- tory, aggressive NHL. https://clinicaltrials.gov/ct2/show/NCT01101581. Accessed August 15, 2015.
  151. ClinicalTrials.gov. A randomized, open-label, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma. https://clinicaltrials.gov/ct2/show/NCT01712490. Accessed August 13, 2015.
  152. ClinicalTrials.gov. A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. https://clinicaltrials.gov/ ct2/show/NCT01777152. Accessed August 13, 2015.
  153. Chen RW, Palmer J, Martin P, et al. Results of a phase II trial of brentuximab ve- dotin as first line salvage therapy in relapsed/refractory HL prior to AHCT.Blood. 2014;124(21):501-501.
  154. 154. Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma:
a non-randomised, open-label, single-centre, phase 2 study.Lancet Oncol. 2015;16(3):284-292.
  155. LaCasce A, Bociek R, Matous J, et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. December 2014. https://ash.confex.com/ash/2014/webpro- gram/Paper67044.html. Accessed August 18, 2015.
  156. ClinicalTrials.gov. A phase 3 trial of brentuximab vedotin(SGN-35) versus physi- cian’s choice (methotrexate or bexarotene) in patients with CD30-positive cutane- ous T-cell lymphoma. https://clinicaltrials.gov/ct2/show/study/NCT01578499. Accessed August 13, 2015.
  157. ClinicalTrials.gov. Brentuximab vedotin and combination chemotherapy in treating younger patients with newly diagnosed hodgkin lymphoma. https://clinicaltrials. gov/ct2/show/NCT02166463. Accessed August 13, 2015.
  158. Mehta A, Forero-Torres A. Development and integration of antibody-drug conjugate in non-Hodgkin lymphoma.Curr Oncol Rep. 2015;17(9):466.
  159. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and prelimi- nary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study.J Clin Oncol. 2010;28(12):2085-2093.
  160. Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non- Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.J Clin Oncol. 2013;31(5):573-583.
  161. Wagner-Johnston ND, Goy A, Rodriguez MA, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.Leuk Lymphoma. March 29, 2015:1-7.
  162. ClinicalTrials.gov. Study of inotuzumab ozogamicin + temsirolimus in patients with relapsed or refractory CD22+ B-cell NH Lymphoma (IOSI-LND-001). https:// clinicaltrials.gov/ct2/show/NCT01535989. Accessed August 13, 2015.
  163. ClinicalTrials.gov. A trial of pembrolizumab (MK-3475) in participants with blood cancers (MK-3475-013)(KEYNOTE-013). https://clinicaltrials.gov/ct2/show/ NCT01953692. Accessed August 13, 2015.
  164. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.Leukemia. 2011;25(2):341-347.
  165. ClinicalTrials.gov. Epigenetic modulation in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). https://clinicaltrials.gov/ct2/show/NCT00978432. Accessed August 13, 2015.
  166. ClinicalTrials.gov. Safety and efficacy of AEB071 and EVEROLIMUS in patients with CD79-mutant or ABC subtype diffuse large B-cell lymphoma (COE- B071X2103). https://clinicaltrials.gov/ct2/show/NCT01854606. Accessed August 13, 2015.
  167. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refrac- tory mantle cell lymphoma.J Clin Oncol. 2009;27(23):3822-3829.
  168. ClinicalTrials.gov. Comparison of 2 doses of temsirolimus (Torisel) in patients with mantle cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT01180049. Ac- cessed August 13, 2015.
  169. ClinicalTrials.gov. Efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (Yosemite). https://clinicaltrials.gov/ct2/show/NCT01732913. Accessed August 13, 2015.
  170. Flinn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL.Blood. 2014;124(21):802-802.
  171. Horwitz SM, Porcu P, Flinn I, et al. Duvelisib (IPI-145), a phosphoinositide-3- kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma.Blood. 2014;124(21):803-803.
  172. Davids M, Seymour J, Gerecitano J, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.Haematologica. 2014;99: Abstract S1348.
  173. ClinicalTrials.gov. A study to compare the efficacy and safety of obinutuzumab + GDC-0199 versus obinutuzumab + chlorambucil in patients with chronic lym- phocytic leukemia. https://clinicaltrials.gov/ct2/show/NCT02242942. Accessed August 13, 2015.